NASDAQ:APRE

Aprea Therapeutics Stock Forecast, Price & News

$4.26

+0.03 (+0.71 %)

(As of 07/27/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.12

▼

$4.43

50-Day Range

$4.05

▼

$5.63

52-Week Range

$3.88

▼

$31.45

Volume784,992 shs

Average Volume2.33 million shs

Market Capitalization$90.26 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.01

30 days | 90 days | 365 days | Advanced Chart

Receive APRE News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Aprea Therapeutics Shares Rise 7% on Positive Data for Eprenetapopt Trial
July 22, 2021 | marketwatch.com

Karolinska Development’s portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt
July 22, 2021 | finance.yahoo.com

Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant
July 21, 2021 | finance.yahoo.com

BRIEF-Aprea Therapeutics Announces Positive Results From Trial Of Eprenetapopt + Azacitidine
July 21, 2021 | msn.com

Analyzing Aprea Therapeutics's Unusual Options Activity
July 21, 2021 | benzinga.com

Aprea Therapeutics Climbs 3% On Positive Study Results Of Its Lead Drug
July 21, 2021 | markets.businessinsider.com

Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
July 21, 2021 | finance.yahoo.com

Traders Buy High Volume of Call Options on Aprea Therapeutics (NASDAQ:APRE)
July 21, 2021 | americanbankingnews.com

Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Growth in Short Interest
July 19, 2021 | americanbankingnews.com

Aprea Therapeutics, Inc. (NASDAQ:APRE) Receives Average Rating of "Hold" from Analysts
July 14, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APRE
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.aprea.com
Phone609-510-4718
Employees11
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.65 per share
Price / Book1.17

Profitability

EPS (Most Recent Fiscal Year)($2.53)
Net Income$-53,480,000.00
Net MarginsN/A
Return on Equity-64.05%
Return on Assets-55.01%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares21,187,000
Market Cap$90.26 million
Next Earnings Date8/10/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.93 out of 5 stars

Medical Sector

711th out of 2,218 stocks

Pharmaceutical Preparations Industry

340th out of 869 stocks

3.1 Analyst's Opinion

Consensus Rating
Aprea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.25, Aprea Therapeutics has a forecasted upside of 234.5% from its current price of $4.26.
Amount of Analyst Coverage
Aprea Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Aprea Therapeutics has received 30 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Aprea Therapeutics has received 27 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Aprea Therapeutics has received 52.63% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aprea Therapeutics and other stocks. Vote “Outperform” if you believe APRE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APRE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Aprea Therapeutics does not currently pay a dividend.
Dividend Growth
Aprea Therapeutics does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
52.20% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.17% of the stock of Aprea Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($1.81) to ($1.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aprea Therapeutics is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aprea Therapeutics is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aprea Therapeutics has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Aprea Therapeutics (NASDAQ:APRE) Frequently Asked Questions

Is Aprea Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Aprea Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APRE, but not buy additional shares or sell existing shares.
View analyst ratings for Aprea Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Aprea Therapeutics?

Wall Street analysts have given Aprea Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aprea Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aprea Therapeutics?

Aprea Therapeutics saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 1,090,000 shares, a drop of 42.3% from the June 30th total of 1,890,000 shares. Based on an average daily trading volume, of 3,330,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 7.4% of the shares of the company are sold short.
View Aprea Therapeutics' Short Interest.

When is Aprea Therapeutics' next earnings date?

Aprea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Aprea Therapeutics.

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) released its earnings results on Thursday, May, 6th. The company reported ($0.46) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $0.03.
View Aprea Therapeutics' earnings history.

How has Aprea Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Aprea Therapeutics' stock was trading at $32.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APRE shares have decreased by 86.9% and is now trading at $4.26.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for APRE?

6 equities research analysts have issued 12 month price targets for Aprea Therapeutics' shares. Their forecasts range from $6.00 to $37.00. On average, they expect Aprea Therapeutics' stock price to reach $14.25 in the next year. This suggests a possible upside of 234.5% from the stock's current price.
View analysts' price targets for Aprea Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Aprea Therapeutics' key executives?

Aprea Therapeutics' management team includes the following people:

Mr. Christian S. Schade, Pres, CEO & Chairman (Age 60, Pay $798.25k)
Mr. Scott M. Coiante, Sr. VP, Company Sec. & CFO (Age 54, Pay $512.45k)
Dr. Eyal C. Attar M.D., Sr. VP & Chief Medical Officer (Age 50, Pay $630.36k)
Dr. Lars B. Abrahmsen, Sr. VP & Chief Scientific Officer (Age 64)
Dr. Gregory A. Korbel Ph.D., Sr. VP & Chief Bus. Officer (Age 45)

Who are some of Aprea Therapeutics' key competitors?

Some companies that are related to Aprea Therapeutics include BioDelivery Sciences International (BDSI), CytomX Therapeutics (CTMX), Nature's Sunshine Products (NATR), Foghorn Therapeutics (FHTX), Altimmune (ALT), Athenex (ATNX), Athersys (ATHX), Theratechnologies (THTX), Oncorus (ONCR), Aeglea BioTherapeutics (AGLE), Verona Pharma (VRNA), Angion Biomedica (ANGN), UroGen Pharma (URGN), Cue Biopharma (CUE) and Puma Biotechnology (PBYI).
View all of APRE's competitors.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Axon Enterprise (AAXN), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).

When did Aprea Therapeutics IPO?

(APRE) raised $52 million in an initial public offering on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

What is Aprea Therapeutics' stock symbol?

Aprea Therapeutics trades on the NASDAQ under the ticker symbol "APRE."

How do I buy shares of Aprea Therapeutics?

Shares of APRE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aprea Therapeutics' stock price today?

One share of APRE stock can currently be purchased for approximately $4.26.

How much money does Aprea Therapeutics make?

Aprea Therapeutics has a market capitalization of $90.26 million. The company earns $-53,480,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does Aprea Therapeutics have?

Aprea Therapeutics employs 11 workers across the globe.

What is Aprea Therapeutics' official website?

The official website for Aprea Therapeutics is www.aprea.com.

Where are Aprea Therapeutics' headquarters?

Aprea Therapeutics is headquartered at 535 BOYLSTON STREET, BOSTON MA, 02116.

How can I contact Aprea Therapeutics?

Aprea Therapeutics' mailing address is 535 BOYLSTON STREET, BOSTON MA, 02116. The company can be reached via phone at 609-510-4718 or via email at [email protected]

This page was last updated on 7/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here